Latest Commercialization News

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Green360 Technologies has made significant strides in commercialising its low-carbon cement product Eco-Clay, delivering successful large-scale trials and securing a robust financial footing heading into 2026.

FortifAI Limited has acquired FastAI and its cutting-edge Nol8 Technology, driving a 14.7% revenue increase and delivering positive net operating cash flow for the first time in Q2 FY26.

IODM Limited has reported a standout Q2 FY26 with record cash receipts driven by strong UK education sector growth and strategic board renewal.

NoviqTech has formalised a key collaboration with Viva Energy on sustainable aviation fuel and agreed to acquire biochar carbon removal specialist Coralia, backed by a $1.5 million capital raise.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

AKORA Resources has completed a significant trenching program at its Bekisopa iron ore project in Madagascar and submitted a mining permit application under a revitalised regulatory framework, gaining strong government backing.

TerraCom Limited reported a stable operational quarter despite logistical challenges impacting coal shipments and cash flow, while successfully raising A$60 million to bolster liquidity. The Blair Athol mine life was extended to 2033, underpinning the company’s long-term outlook.

Mont Royal Resources has kicked off a comprehensive work program at its Ashram Rare Earth and Fluorspar Project following a transformative merger and a successful $10 million capital raise. An updated Preliminary Economic Assessment is expected by the end of Q1 2026.

Alexium International Group has acquired Microtek Laboratories’ microencapsulation business, marking a strategic pivot to manufacturing-led growth and raising $4.6 million to fund expansion. Despite a slight sales dip, the company is poised for a stronger 2026 with new product lines and military trials underway.

VBX Limited has reported a significant 51% increase in its Wuudagu bauxite resource and enhanced its project feasibility study, supported by fresh funding and robust market conditions.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.